These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10868304)

  • 41. Levothyroxine dosage and the limitations of current bioequivalence standards.
    Hennessey JV
    Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756
    [No Abstract]   [Full Text] [Related]  

  • 42. Comparative bioavailability of Mazetol and Tegretol.
    Batham AK
    J Assoc Physicians India; 1989 Jun; 37(6):413-4. PubMed ID: 2592338
    [No Abstract]   [Full Text] [Related]  

  • 43. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach.
    Idkaidek NM; Al-Ghazawi A; Najib NM
    Biopharm Drug Dispos; 2004 Dec; 25(9):367-72. PubMed ID: 15495146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Harmonization of testing drugs for bioequivalence: problems and possible solutions].
    Zherdev VP; Kolyvanov GB; Litvin AA; Sariev AK
    Eksp Klin Farmakol; 2003; 66(2):60-4. PubMed ID: 12962051
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative bioavailability of two brands of carbamazepine. Reply from the authors.
    Bhatt AD
    J Assoc Physicians India; 1989 Sep; 37(9):619-20. PubMed ID: 2698888
    [No Abstract]   [Full Text] [Related]  

  • 47. Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel.
    Tettey-Amlalo RN; Kanfer I; Skinner MF; Benfeldt E; Verbeeck RK
    Eur J Pharm Sci; 2009 Feb; 36(2-3):219-25. PubMed ID: 18848881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the bioavailability of MST Continus tablets and Oramorph SR tablets.
    Miller AJ; Smith KJ
    Palliat Med; 1996 Oct; 10(4):349-50. PubMed ID: 8931080
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug Product Selection--Part 2: Scientific basis of bioavailability and bioequivalence testing.
    Meyer MC
    Am Pharm; 1991 Aug; NS31(8):47-52. PubMed ID: 1927900
    [No Abstract]   [Full Text] [Related]  

  • 50. Bioequivalence of isoniazid in a two drug fixed dose combination and in a single drug dosage form.
    Agrawal S; Kaul CL; Panchagnula R
    Pharmazie; 2001 Aug; 56(8):636-9. PubMed ID: 11534341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers.
    Mignini F; Streccioni V; Tomassoni D; Traini E; Amenta F
    Clin Exp Hypertens; 2007 Nov; 29(8):575-86. PubMed ID: 18058482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative bioavailability of two formulations of azithromycin.
    Gulati R; Tripathi CD; Chandra D
    J Assoc Physicians India; 2000 Jun; 48(6):606-8. PubMed ID: 11273540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interchangeability of oral contraceptive products. Expert Advisory Committee on Bioavailability, Health Protection Branch, Department of National Health and Welfare.
    CMAJ; 1991 May; 144(10):1223-4. PubMed ID: 2025817
    [No Abstract]   [Full Text] [Related]  

  • 55. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Half-life revisited: implication in clinical trials and bioavailability/bioequivalence evaluation.
    Chen ML; Pelsor FR
    J Pharm Sci; 1991 Apr; 80(4):406-8. PubMed ID: 1865346
    [No Abstract]   [Full Text] [Related]  

  • 58. BIO-international '94 Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies and Pre-Conference Satellite on 'In Vivo/In Vitro Correlation'. Munich, Germany, June 14-17, 1994.
    Blume HH; McGilveray IJ; Midha KK
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):3-13. PubMed ID: 7588991
    [No Abstract]   [Full Text] [Related]  

  • 59. Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.
    Williams RL; Adams W; Chen ML; Hare D; Hussain A; Lesko L; Patnaik R; Shah V
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):7-12. PubMed ID: 11032082
    [No Abstract]   [Full Text] [Related]  

  • 60. Bioequivalence assessment and the conduct of bioequivalence trials: a European point of view.
    Herchuelz A
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):149-52. PubMed ID: 8839688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.